Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study.


Journal

Advances in rheumatology (London, England)
ISSN: 2523-3106
Titre abrégé: Adv Rheumatol
Pays: England
ID NLM: 101734172

Informations de publication

Date de publication:
07 04 2021
Historique:
received: 21 08 2020
accepted: 25 03 2021
entrez: 8 4 2021
pubmed: 9 4 2021
medline: 31 12 2021
Statut: epublish

Résumé

To compare the incidence of osteoporotic fractures in patients with rheumatoid arthritis (RA) with matched controls from a university hospital. Consecutive RA patients (n = 100) were matched (age and sex) with controls (1:2). The follow-up period began at the index date, defined as the date of diagnosis for RA patients and the date of the first medical claim at the Health Management Organization (HMO) for non-RA patients. Fracture incidence rates per 1000 persons-years (PY) for distinct types of fractures were calculated. Multivariate cox regression analysis was performed to identify factors associated with fractures. One hundred RA patients were followed for a total of 975.1 patients-years and 200 controls for 1485.7 patients-years. No difference was found in the overall fracture incidence rate per 1000 PY between RA and controls (19.5, 95% CI 12.7-28.6 vs 12.1, 95% CI 7.7-18.7, p = 0.07). In the Cox regression analysis, only age (HR 1.06, 95% CI 1.02-1.11, p = 0.006) and history of a prior fracture (HR 9.85, 95% CI 2.97-32.64, p <  0.001) were associated with fractures after the index date. The stratified analysis of the fractures by location showed that only the vertebral fractures were more frequent in RA patients compared with controls (12.9 per 1000 PY, 95% CI 8.9-25.8, vs. 3.4, 95% CI 1.4-8.1, respectively, p = 0.01). Patients with RA didn't show an overall increased risk of osteoporotic fractures compared with matched controls, but vertebral fractures were more frequently observed in patients with RA.

Sections du résumé

BACKGROUND
To compare the incidence of osteoporotic fractures in patients with rheumatoid arthritis (RA) with matched controls from a university hospital.
METHODS
Consecutive RA patients (n = 100) were matched (age and sex) with controls (1:2). The follow-up period began at the index date, defined as the date of diagnosis for RA patients and the date of the first medical claim at the Health Management Organization (HMO) for non-RA patients. Fracture incidence rates per 1000 persons-years (PY) for distinct types of fractures were calculated. Multivariate cox regression analysis was performed to identify factors associated with fractures.
RESULTS
One hundred RA patients were followed for a total of 975.1 patients-years and 200 controls for 1485.7 patients-years. No difference was found in the overall fracture incidence rate per 1000 PY between RA and controls (19.5, 95% CI 12.7-28.6 vs 12.1, 95% CI 7.7-18.7, p = 0.07). In the Cox regression analysis, only age (HR 1.06, 95% CI 1.02-1.11, p = 0.006) and history of a prior fracture (HR 9.85, 95% CI 2.97-32.64, p <  0.001) were associated with fractures after the index date. The stratified analysis of the fractures by location showed that only the vertebral fractures were more frequent in RA patients compared with controls (12.9 per 1000 PY, 95% CI 8.9-25.8, vs. 3.4, 95% CI 1.4-8.1, respectively, p = 0.01).
CONCLUSION
Patients with RA didn't show an overall increased risk of osteoporotic fractures compared with matched controls, but vertebral fractures were more frequently observed in patients with RA.

Identifiants

pubmed: 33827708
doi: 10.1186/s42358-021-00179-3
pii: 10.1186/s42358-021-00179-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Références

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001;285(6):785–795. https://doi.org/10.1001/jama.285.6.785 .
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
Siris ES, Chen Y-T, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–12. https://doi.org/10.1001/archinte.164.10.1108 .
doi: 10.1001/archinte.164.10.1108 pubmed: 15159268
Mosquera MT, Maurel DL, Pavón S, Arregui A, Moreno C, Vázquez J. Incidencia y factores de riesgo de la fractura de fémur proximal por osteoporosis [Incidence and risk factors in fractures of the proximal femur due to osteoporosis]. Rev Panam Salud Publica. 1998;3(4):211–9. Spanish. https://doi.org/10.1590/s1020-49891998000400001 .
Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–6. https://doi.org/10.1002/jbmr.2269 .
doi: 10.1002/jbmr.2269 pubmed: 24771492 pmcid: 4757905
Wittich A, Bagur A, Mautalen C, Cristofari A, Escobar O, Carrizo G, et al. Epidemiology of hip fracture in Tucuman. Argentina. Osteoporos Int. 2010;21(11):1803–7. https://doi.org/10.1007/s00198-009-1135-3 .
doi: 10.1007/s00198-009-1135-3 pubmed: 19997904
Morosano M, Masoni A, Sánchez A. Incidence of hip fractures in the city of Rosario. Argentina Osteoporos Int. 2005;16(11):1339–44. https://doi.org/10.1007/s00198-005-1839-y .
doi: 10.1007/s00198-005-1839-y pubmed: 15841335
Bagur A, Mautalen C, Rubin Z. Epidemiology of hip fractures in an urban population of Central Argentina. Osteoporos Int. 1994;4(6):332–5. https://doi.org/10.1007/BF01622193 .
doi: 10.1007/BF01622193 pubmed: 7696828
Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American vertebral osteoporosis study (LAVOS). Osteoporos Int. 2009;20(2):275–82. https://doi.org/10.1007/s00198-008-0657-4 .
doi: 10.1007/s00198-008-0657-4 pubmed: 18584111
Harvey N, Dennison E, bone CC-P on the metabolic, 2008 undefined. Epidemiology of osteoporotic fractures. books.google.com .
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–7. https://doi.org/10.1016/S0140-6736(02)08657-9 .
doi: 10.1016/S0140-6736(02)08657-9 pubmed: 12049882
Scublinsky D, Venarotti H, Citera G, Messina OD, Scheines E, Rillo O, et al. The prevalence of rheumatoid arthritis in Argentina. JCR J Clin Rheumatol. 2010;16(7):317–21. https://doi.org/10.1097/RHU.0b013e3181f3bfdd .
doi: 10.1097/RHU.0b013e3181f3bfdd pubmed: 20859227
Di WT, Vergara F, Bertiller E, de LA Gallardo M, Gandino I, Scolnik M, et al. Incidence and Prevalence of Rheumatoid Arthritis in a Health Management Organization in Argentina: A 15-year Study. J Rheumatol. 2016;43(7):1306–11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27084906 . [cited 2020 Apr 16].
doi: 10.3899/jrheum.151262
Goldring SR. Inflammatory signaling induced bone loss. Bone. 2015;80:143–9. https://doi.org/10.1016/j.bone.2015.05.024 .
doi: 10.1016/j.bone.2015.05.024 pubmed: 26027506
Heinlen L, Humphrey MB. Skeletal complications of rheumatoid arthritis. Osteoporos Int. 2017;28(10):2801–12. https://doi.org/10.1007/s00198-017-4170-5 .
doi: 10.1007/s00198-017-4170-5 pubmed: 28779302
Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–9. https://doi.org/10.1002/art.11283 .
doi: 10.1002/art.11283 pubmed: 14613287
Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang C-L, Garneau K, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R154. https://doi.org/10.1186/ar3107 .
doi: 10.1186/ar3107 pubmed: 20682035 pmcid: 2945054
Lane NE, Pressman AR, Star VL, Cummings SR, Nevitt MC. Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res. 2009;10(2):257–63. https://doi.org/10.1002/jbmr.5650100212 .
doi: 10.1002/jbmr.5650100212
Cheng T-T, Lai H-M, Yu S-F, Chiu W-C, Hsu C-Y, Chen J-F, et al. The impact of low-dose glucocorticoids on disease activity, bone mineral density, fragility fractures, and 10-year probability of fractures in patients with rheumatoid arthritis. J Investig Med. 2018;66(6):1004–7. https://doi.org/10.1136/jim-2018-000723 .
doi: 10.1136/jim-2018-000723 pubmed: 29891493 pmcid: 6073913
Pierini FS, Scolnik M, Scaglioni V, Mollerach F, Soriano ER. Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. Clin Rheumatol. 2019;38(7):1935–40. https://doi.org/10.1007/s10067-019-04463-y .
Rosa J, Garrot LF, Navarta DA, Saucedo C, Scolnik M, Bedran Z, et al. Incidence and prevalence of Polymyositis and Dermatomyositis in a health Management Organization in Buenos Aires. J Clin Rheumatol. 2013;19(6):303–7. https://doi.org/10.1097/RHU.0b013e3182a21ba8 .
doi: 10.1097/RHU.0b013e3182a21ba8 pubmed: 23965482
Soriano ER, Rosa J, Velozo E, Schpilberg M, Imamura PM, Diaz J, et al. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology. 2011;50(4):729–34. https://doi.org/10.1093/rheumatology/keq369 .
doi: 10.1093/rheumatology/keq369 pubmed: 21134962
Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS, Avellaneda NL, et al. Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. Lupus Sci Med. 2014;1(1):e000021. https://doi.org/10.1136/lupus-2014-000021 .
doi: 10.1136/lupus-2014-000021 pubmed: 25379189 pmcid: 4213830
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584 .
doi: 10.1002/art.27584 pubmed: 20872595
Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–48 Available from: https://pubmed.ncbi.nlm.nih.gov/8237484/ . [cited 2021 Feb 9].
doi: 10.1002/jbmr.5650080915
Fragility fractures | International Osteoporosis Foundation [Internet]. [cited 2021 Feb 10]. Available from: https://www.osteoporosis.foundation/health-professionals/fragility-fractures
Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115–21. https://doi.org/10.1016/j.bone.2008.08.106 .
doi: 10.1016/j.bone.2008.08.106 pubmed: 18793764
Kanis JA, Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporos Int. 1994;4(6):368–81. https://doi.org/10.1007/BF01622200 [cited 2021 Feb 23].
doi: 10.1007/BF01622200 pubmed: 7696835
Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporosis Int. 2017;28:3301–14.
doi: 10.1007/s00198-017-4189-7
Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S, et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the glucocorticoid induced OsTeoporosis TOol (GIOTTO) study. Reumatismo. 2017;69(1):30. https://doi.org/10.4081/reumatismo.2017.922 .
doi: 10.4081/reumatismo.2017.922 pubmed: 28535619
Akkawi I, Zmerly H. Osteoporosis: current concepts. Joints. 2018;6:122–7.
doi: 10.1055/s-0038-1660790
Kim D, Cho S-K, Park B, Jang EJ, Bae S-C, Sung Y-K. Glucocorticoids are associated with an increased risk for vertebral fracture in patients with rheumatoid arthritis. J Rheumatol. 2018 May;45(5):612–20. https://doi.org/10.3899/jrheum.170054 .
doi: 10.3899/jrheum.170054 pubmed: 29545455
Jin S, Hsieh E, Peng L, Yu C, Wang Y, Wu C, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018;29(6):1263–75. https://doi.org/10.1007/s00198-018-4473-1 .
doi: 10.1007/s00198-018-4473-1 pubmed: 29546507
Van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3104–12. https://doi.org/10.1002/art.22117 .
doi: 10.1002/art.22117 pubmed: 17009229
Xue A-L, Wu S-Y, Jiang L, Feng A-M, Guo H-F, Zhao P. Bone fracture risk in patients with rheumatoid arthritis. Medicine (Baltimore). 2017;96(36):e6983. https://doi.org/10.1097/MD.0000000000006983 .
doi: 10.1097/MD.0000000000006983
Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–9. https://doi.org/10.1016/S0140-6736(04)16676-2 .
doi: 10.1016/S0140-6736(04)16676-2 pubmed: 15262104
Killinger Z, Gajdarova L, Kuzma M, Krajcovicova A, Brazdilova K, Jackuliak P, et al. Biologic treatment in comparison to methotrexate has positive effect on trabecular bone score in rheumatoid arthritis patients: 1-year follow-up. Acta Clin Belg. 2019;74(2):121–5. https://doi.org/10.1080/17843286.2018.1512189 . Epub 2018 Aug 23.
Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, et al. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int. 2017;28(2):429–46. https://doi.org/10.1007/s00198-016-3769-2 .
doi: 10.1007/s00198-016-3769-2 pubmed: 27796445
Ballane G, Cauley JA, Luckey MM, El-Hajj FG. Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int. 2017;28(5):1531–42. https://doi.org/10.1007/s00198-017-3909-3 .
doi: 10.1007/s00198-017-3909-3 pubmed: 28168409 pmcid: 28168409

Auteurs

Florencia S Pierini (FS)

Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, Perón 4190, 1181, Buenos Aires, Argentina. florpierini@gmail.com.

Martin Brom (M)

Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, Perón 4190, 1181, Buenos Aires, Argentina.

Marina Scolnik (M)

Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, Perón 4190, 1181, Buenos Aires, Argentina.

Valeria Scaglioni (V)

Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, Perón 4190, 1181, Buenos Aires, Argentina.

Javier E Rosa (JE)

Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, Perón 4190, 1181, Buenos Aires, Argentina.

Enrique R Soriano (ER)

Rheumatology Unit, Internal Medicine Department, Hospital Italiano de Buenos Aires, Perón 4190, 1181, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH